Popular terms

Immunotherapy topics
Immunotherapy
Therapeutics
Antibodies
Immune Response
Monoclonal
Monoclonal Antibody
Stimulator
Immunostimulator
Compatibility
Histocompatibility
Specificity
Major Histocompatibility Complex
Radiation Therapy
Treatments
Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immunotherapy patents



      

This page is updated frequently with new Immunotherapy-related patent applications.




Date/App# patent app List of recent Immunotherapy-related patents
02/04/16
20160032004 
 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity patent thumbnailDosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg.
Immunomedics, Inc.


02/04/16
20160031976 
 Tau immunotherapy patent thumbnailTau immunotherapy
The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration..
Prothena Biosciences Limited


02/04/16
20160031946 
 Multi-epitopic vaccine patent thumbnailMulti-epitopic vaccine
The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of zebra or a fragment thereof that retains the capacity of internalization, (ii) at least one cd4+ epitope; and (iii) at least one cd8+ epitope. It also relates to antigen presenting cells loaded with said polypeptides, and the use thereof in immunotherapy including prevention and/or treatment of cancers or infectious diseases..
Hopitaux Universitaires De Geneve


02/04/16
20160030539 
 Cancer testis antigen sperm protein 17 as a target for breast cancer immunotherapy and diagnosis patent thumbnailCancer testis antigen sperm protein 17 as a target for breast cancer immunotherapy and diagnosis
The present invention includes compositions and methods for treating a breast cancer cell, a metastatic breast cancer cell, or a triple negative breast cancer cell comprising: identifying a subject in need for treatment for a breast cancer cell, a metastatic breast cancer cell, or a triple negative breast cancer cell; and administering a therapeutically effective amount of a formulation that leads to the presentation of an immunogenic sp17 protein or peptide antigen on an antigen presenting cell to activate t cells that are sp17-specific t cells, wherein the sp17-specific t cells impair the growth of the breast cancer cell, the metastatic breast cancer cell, or the triple negative breast cancer cell growth.. .
Texas Tech University System


02/04/16
20160030289 
 Manufacture of peanut formulations for oral desensitization patent thumbnailManufacture of peanut formulations for oral desensitization
The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies..
Aimmune Therapeutics, Inc.


01/28/16
20160026765 
 Immunotherapy system and method thereof patent thumbnailImmunotherapy system and method thereof
An aspect of the invention generally relates to an immunotherapy system and method thereof, and more particularly to a method and system for providing, generating, tracking an immunotherapy treatment.. .
Phd Preventative Health Care And Diagnostics, Inc.


01/28/16
20160024472 
 Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines patent thumbnailGeneration of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines
The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only gm-csf without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as il-4 or il-13, to prevent differentiation into a non-dendritic cell lineage.
Northwest Biotherapeutics, Inc.


01/28/16
20160024469 
 Non-conventional cellular based immunotherapy patent thumbnailNon-conventional cellular based immunotherapy
Most importantly non-obviousness of this patent is clearly elucidated in the proposed method of immunotherapy whereby cancer stem cells (either directly isolated in culture or created by an induced process like ipscs) are lysed for their protein antigens and electroporated or incubated with novel immunogenic cells (not dendritic cells) such as svf and given back to the same patient in an autologous and personalized fashion. (in this way both mhc i and mhc ii pathways may be utilized and a plurality of non-dendritic cells with antigen presenting capabilities are advantageously used in a plural immune like fashion raising immunogenicity through multiple novel and unique epitopes..

01/28/16
20160024175 
 Chemotherapy-resistant immune cells patent thumbnailChemotherapy-resistant immune cells
Embodiments of the disclosure include compositions and methods useful for treating cancers that are sensitive to a chemotherapy, such as temozolomide. The methods allow effective cell immunotherapy to be used with chemotherapy when the cell immunotherapy is susceptible to being rendered ineffective by the chemotherapy.
Baylor College Of Medicine


01/28/16
20160022808 
 Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic sendai virus patent thumbnailMethod for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic sendai virus
The invention relates to the field of immunology and medicine, more specifically, oncology, and can be useful for the treatment of patients with carcinomas and sarcomas. A pharmaceutical composition is provided which contains biologically active oncolytic sendai virus strain moscow pta-13024, and a method of treating patients with said malignancies is developed including administration of the said composition to a patient's body.

01/28/16
20160022728 

Mirna for treating cancer and for use with adoptive immunotherapies


In some aspects, mirna for the treatment of cancer are provided. In some embodiments, a mirna (e.g., mir-124, mir-142, and/or mir-138) may be used to promote or enhance immune destruction of a cancer, or reduce the immune suppression of the cancer, in a subject.
Board Of Regents, The University Of Texas System


01/21/16
20160017011 

Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy


Pharmaceutical compositions and methods for regulating somatic cell reprogramming in mammals, and in particular, for positively and negatively regulating cell reprogramming in human cells in vivo and in vitro. The invention also provides phf20-derived compositions and methods useful for cancer immunotherapies, including breast cancer therapies in particular..

01/21/16
20160015751 

Method for enhancing a function of a t cell


Disclosed is a method for enhancing the function of a t cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (pd-l1) and/or programmed death-1 ligand 2 (pd-l2) in the t cell. Also disclosed is a function-enhanced t cell which is produced by the function enhancement method.
Takara Bio Inc.


01/21/16
20160015749 

Engager cells for immunotherapy


Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule.
Celgene Corporation


01/14/16
20160009816 

Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy


The present invention relates generally to the membrane transporter napi2b (slc34a2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The slc34a2 epitope peptide encompassing amino acids 312-340 of slc34a2 has been identified as an ovarian cancer epitope using the monoclonal antibody mx35.

01/14/16
20160009813 

Effective generation of tumor-targeted t cells derived from pluripotent stem cells


The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and/or expandable t cells from pluripotent stem cells engineered through safe genetic modifications.
Memorial Sloan-kettering Cancer Center


01/14/16
20160008448 

Rhoc-based immunotherapy


The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; ras homology gene family, member c (rhoc) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses.
Rhovac Aps


01/14/16
20160008447 

Compositions and methods of identifying tumor specific neoantigens


The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses..
The General Hospital Corporation


01/14/16
20160008445 

Kntc2 peptides and vaccines containing the same


Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the kntc2 gene that elicit ctls and thus are suitable for use in the context of cancer immunotherapy are provided.
Oncotherapy Science, Inc.


01/14/16
20160008388 

Compositions and methods for immunotherapy


The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.

01/14/16
20160008345 

Methods for treating gliomas with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione


Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation


01/07/16
20160002731 

Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization


Disclosed are methods for determining the immunological status of the adaptive immune system of a subject by identifying and quantifying rearranged dna (and/or subsequently transcribed rna) sequences encoding t cell receptor (tcr) and/or immunoglobulin (ig) polypeptides, in a lymphoid dna-containing sample from the subject. Tcr and/or ig sequence diversity and sequence distribution permit immunocompetence and immune repertoire assessment and reflect the degree of t cell or b cell clonality and clonal expansion in the sample.
Memorial Sloankettering Cancer Center


01/07/16
20160002334 

Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions


Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors pd-1 and tim-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer..
The Brigham And Women's Hospital, Inc.


01/07/16
20160002333 

Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


12/31/15
20150376296 

Compositions and methods for immunotherapy


The present invention provides immunoresponsive cells, including t cells, cytotoxic t cells, regulatory t cells, and natural killer (nk) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (icar). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired..
Memorial Sloan-kettering Cancer Center


12/31/15
20150374734 

Activation of inkt cells


The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv.
Institut Pasteur De Lille


12/24/15
20150368612 

Methods and compositions for treating breast cancer with dendritic cell vaccines


Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin b1 and wt-1 peptide antigens for immunotherapy.
Baylor Research Institute


12/24/15
20150368328 

Immunotherapy for clearing pathological tau conformers


The present invention relates to methods of treating and preventing alzheimer's disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent alzheimer's disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject..
New York University


12/24/15
20150368298 

Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


12/24/15
20150366988 

Antibody-drug conjugates and uses thereof


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to trop-2 or ceacam5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg.
Immunomedics, Inc.


12/17/15
20150359876 

Generation of broadly-specific, virus-immune cells targeting multiple hiv antigens for preventive and therapeutic use


Compositions for t cell-based immunotherapy of hiv, hiv-associated malignancies, hiv-associated viral infections, or other hiv-related complications. Modified t cells that are resistant to invasion or infection with hiv, such as t-cells modified to decrease or eliminate expression of mannosyl-oligosacharide glucosidase enzyme (“mogs”).
Children's National Medical Center


12/10/15
20150352208 

Inhibition of cxcr4 signaling in cancer immunotherapy


The inventions describes a method for increasing effector t cell accumulation in cancer cell-containing sites of a tumor, comprising administering to a subject in need thereof a pharmaceutically effective amount of an inhibitor of cxcr4 signaling.. .
Cambridge Enterprise Limited


12/03/15
20150344553 

Human anti-tau antibodies


Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed.
Biogen Idec Internatioanl Neuroscience Gmbh


12/03/15
20150343075 

Placebo formulations and uses thereof


The present technology relates to placebo compositions and their use in clinical trials for oral immunotherapy of peanut allergies. Therapy can be treatment or desensitization of peanut allergies.
Aimmune Therapeutics


12/03/15
20150342993 

Compositions and methods for immunotherapy


The present invention provides immunoresponsive cells, including t cells, cytotoxic t cells, regulatory t cells, and natural killer (nk) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired..
Memorial Sloan-kettering Cancer Center


12/03/15
20150342925 

Use of antioxidants as an adjuvant to immune stimulators to augment tumor immunity and prevent toxicity associated with oxidative stress


The current application teaches methods and compositions useful for the treatment of cancer through administration of an antioxidant together with an immune stimulator at concentrations sufficient to augment antitumor immunity while simultaneously preventing inhibition of t cell function as a result of tumor secreted oxidative stress. Compositions such as toll like receptor agonists in combination with antioxidants are disclosed.
Batu Biologics


11/26/15
20150335679 

Methods and compositions for treating malignancies with dendritic cells


This invention provides methods and compositions for the treatment and/or prevention of cancer, including solid malignancies and hematologic malignancies. In particular, the present invention relates to immunotherapy using antigen-presenting cells loaded with tumor associated peptide antigens (tapas).
Kiromic, Llc


11/19/15
20150329640 

Chimeric antigen receptors and immune cells targeting b cell malignancies


The disclosure describes genetically engineered cd37 specific redirected immune effector cells expressing a chimeric antigen receptor (car) protein comprising an antigen binding domain derived from an antibody, a single chain antibody or portion thereof that binds cd37; a hinge region; a transmembrane domain and an intracellular signaling domain derived from human cd3ζ or fcrγ; and optionally one or more co-stimulatory intracellular signaling domains the invention includes nucleic acids, vectors and immune effector cells associated with the production of the car protein, as well as methods of treating b cell malignancies in humans by cellular immunotherapy.. .
Bluebird Bio, Inc.


11/19/15
20150328199 

Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment of cancers


Methods and compositions for treating, preventing or managing cancers are disclosed. The methods encompass the administration of 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione, also known as pomalidomide.
Celgene Corporation


11/12/15
20150322235 

Organopolysiloxane composition suitable for vulcanisation into an elastomer at room temperature and new organopolysiloxane polycondensation catalysts


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Bluestar Silicones France Sas


11/12/15
20150322112 

Sema5b peptides and vaccines containing the same


Peptide vaccines against cancer are described herein. Isolated epitope peptides derived from the sema5b gene that elicit ctls and thus are suitable for use in the context of cancer immunotherapy are provided.
Oncotherapy Science, Inc.


11/12/15
20150320848 

Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


11/05/15
20150315255 

Immune modulator for immunotherapy and vaccine formulation


A recombinant flagrp170 protein and pharmaceutical compositions comprising a flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The flagrp170 protein comprises an nf-kb-activating domain of flagellin and an atp-binding domain truncated grp170.
Virginia Commonwealth University


10/29/15
20150306198 

Aspartate-ß-hydroxylase induces epitope-specific t cell responses in tumors


The present invention provides a peptide-based immunotherapy for asph-expressing tumors.. .
Rhode Island Hospital


10/29/15
20150306141 

Method and compositions for cellular immunotherapy


The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring cd8+ central memory t cells or combinations of central memory t cells with cd4+ t cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain.
Seattle Children's Hospital, Dba Seattle Children 's Research Institute


10/22/15
20150297310 

Methods for selecting a treatment for cancer


Biomarkers predictive of a subject's likelihood of responding to an immunotherapy including blockade of pd-1 inhibitory signaling, and method of use thereof are disclosed. The biomarkers are hif1-alpha, kdr, cxcl13, and il7r.
Georgia Regents Research Institute, Inc.


10/08/15
20150284445 

Immune receptor modifier conjugate and preparation method and use thereof, coupling precursor for preparing same, and compound for synthesizing coupling precursor


Disclosed is an immune receptor modifier conjugate, obtained from the reaction between a coupling precursor and a biotic ligand, the coupling precursor being a 9-position aminomethyl benzyl purine biotic coupling precursor, and the biotic ligand being selected from one or more of polypeptide, protein, glycoprotein, polysaccharide, polynucleotide, inactivated cells and inactivated microbes. The immune receptor modifier couplet can be used for immunomodulation, antibody preparation, anti-virus, diabetes, tumor immunomodulation, and tumor bio-immunotherapy.

10/08/15
20150283231 

Induction of antigen-specific tolerance by peripheral phagocytosis


The invention relates to a pharmaceutical composition for modulation of t cell and b cell responses by antigen- or allergen-specific immunotherapy in combination with peripheral tolerance-inducing phagocytosis, made of one or more preparations and comprising one or more matrices suitable for locally restricted sustained release of a physiologically effective dose of at least one antigen or allergen, liposomes tailored for effective phagocytosis, one or more immune modulators of phagocytosis, and one or more immune modulators suitable for enhancing the suppressive function of regulatory t cells at the site of antigen or allergen presentation.. .

10/08/15
20150283219 

Universal cancer peptides derived from telomerase


The invention relates to a peptide of 15 to 20 amino acids deriving from tert protein, which peptide is capable of (i) binding to hla class ii and (ii) stimulating a cd4 th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring..

10/01/15
20150275209 

Compositions and methods for enhancing cancer immunotherapy


The invention provides an isolated or purified cd8+? t cell which comprises an antigen-specific t cell receptor and an exogenous nucleic acid encoding a microrna-155 (mir-155) molecule, and methods of preparing the same. The invention also provides a pharmaceutical composition comprising the cd8+ t cell a carrier.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Service


10/01/15
20150273052 

Modification of allergens for immunotherapy


According to a particularly preferred embodiment, the present invention relates to pharmaceutical compositions for immunotherapy comprising reduced and alkylated naturally occurring peanut allergens ara h2 and/or ara h6, or derivates or isoforms thereof wherein said pharmaceutical composition substantially does not comprise ara h1 and/or ara h3.. .

10/01/15
20150273051 

Improved human herpesvirus immunotherapy


An isolated protein comprises respective amino acid sequences of each of a plurality of ctl epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said ctl epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, transporter associated with antigen processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic t lymphocytes (ctl) in vitro and eliciting a ctl immune response in vivo upon administration to an animal as an exogenous protein.
The Council Of The Queensland Institute Of Medical Research


09/24/15
20150268243 

Methods for predicting the sensitivity of a subject to immunotherapy


The present invention relates to a method of assessing, predicting or monitoring the sensitivity of a subject having a tumor or cancer to an immunotherapeutic molecule acting on the subject's t cells, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to the use of corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to an immunotherapeutic molecule acting on the subject's t cells typically comprises a step a) of determining, in a biological sample from said subject, the expression level of soluble cd25 (scd25) and, when the expression level is determined, a step b) of comparing at least said expression level to a reference expression level thereby assessing whether the subject having a tumor is responsive or resistant to the immunotherapeutic molecule..
Institut Gustave Roussy


09/24/15
20150265591 

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias


Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide.
Celgene Corporation


09/10/15
20150252427 

Identification of tumor-protective epitopes for the treatment of cancers


Described herein are methods of identifying tumor-specific epitopes from the cancer tissue dna of cancer patients using both dna sequencing and bioinformatics techniques. The identification of tumor-specific epitopes provides pharmaceutical compositions with a limited number of tumor-specific peptides suitable for personalized genomics-driven immunotherapy of human cancer.
The University Of Connecticut


09/10/15
20150252102 

Human anti-tau antibodies


Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed.
Biogen Idec International Neuroscience Gmbh


09/10/15
20150250870 

Compositions for immunotherapy


The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals suffering from a peanut allergy. The present invention further relates to the use of the present compositions for the treatment of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment for desentizing the immune system of a mammal for an allergen.
Hal Allergy Holding B.v.


09/10/15
20150250868 

Re-directed immunotherapy


The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a t cell antigen, wherein the t cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.. .
The University Of Birmingham


09/10/15
20150250775 

Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders


Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of sns-595.
Sunesis Pharmaceuticals, Inc.


09/03/15
20150247860 

Composition and diagnosis and immunotherapy of prostate cancer


A method and composition for the diagnosis of and treatment of prostate cancer including a recombinant akap-4 tumor-associated antigen loaded antigen presenting cell that generates an akap-4 specific cytotoxic t lymphocyte specific for one or more prostate cancer cells.. .
Texas Tech University System


09/03/15
20150246115 

Composition comprising cytokine macro-aggregates


The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides compositions (e.g., vaccines) and methods of using the same for the induction of immune responses (e.g., innate and adaptive immune responses (e.g., for generation of host immunity against cancer (e.g., a tumor) or against any type of antigen (e.g.
Cytuvax


09/03/15
20150246106 

Prostate-associated antigens and vaccine-based immunotherapy regimens


The present disclosure provides (a) isolated immunogenic paa polypeptides; (b) isolated nucleic acid molecules encoding immunogenic paa polypeptides; (c) vaccine compositions comprising an immunogenic paa polypeptide or an isolated nucleic acid molecule encoding an immunogenic paa polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.. .
Pfizer Inc


08/20/15
20150232542 

Human anti-alpha-synuclein antibodies


Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed.
University Of Zurich


08/13/15
20150224189 

Silicon dioxide nanoparticles and the use thereof for vaccination


The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer.
Merck Patent Gmbh


08/13/15
20150224182 

Target peptides for immunotherapy and diagnostics


A set of target peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive t cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/mhc complex..
U.va. Licensing & Ventures Group


08/13/15
20150224143 

Selective and controlled expansion of educated nk cells


The present invention relates generally to immunotherapy. Disclosed herein are methods for obtaining cytolytic differentiated nkg2a−nkg2c+ cells with a given kir specificity and also compositions comprising these cells as well as the use of these cells for therapy.
Inven2 As


08/06/15
20150218216 

Psf1-derived peptide


The purpose of the present invention is to provide a psf1-derived peptide useful for a specific immunotherapy for cancer patients. The present invention provides: a psf1-derived peptide which can induce a ctl; and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention..
Genestem Co., Ltd.


08/06/15
20150216997 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


08/06/15
20150216843 

Inhibition of cxcr4 signaling in cancer immunotherapy


The inventions describes a method for increasing effector t cell accumulation in cancer cell-containing sites of a tumor, comprising administering to a subject in need thereof a pharmaceutically effective amount of an inhibitor of cxcr4 signaling.. .
Cambridge Enterprise Limited


07/30/15
20150212090 

Use of a panel of urinary cytokines to predict response to bcg therapy for bladder cancer


Methods for predicting cancer recurrence following a bcg immunotherapy are provided. In some aspects, cytokine levels from a patient are measured before and after a bcg therapy and the changes in cytokine levels are used to determine the risk of cancer lapse.
Board Of Regents, The University Of Texas System


07/30/15
20150210759 

Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof


Provided are novel human islet amyloid polypeptide, also known as amylin and iapp and proiapp respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for iapp and/or proiapp are also disclosed.
Neurimmune Holding Ag


07/23/15
20150203817 

Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells


A method of expanding tcralpha deficient t-cells by expressing ptalpha or functional variants thereof into said cells, thereby restoring a functional cd3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary t-cells from donors.
Cellectis


07/23/15
20150203562 

Compounds and methods for modulating pharmacokinetics


Methods and compositions are described for management of the pharmacokinetic properties of active agents, e.g., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (hb). Compounds may be administered to tissues including skin.
The Brigham And Women's Hospital, Inc.


07/23/15
20150202320 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/23/15
20150202319 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196774 

Laser immunotherapy


A method of immunotherapy of a mammal or a laser device therefor, includes the step of treating one or more immune privileged cells, tissue or organs of said mammal with a laser to reduce or eliminate the immune privilege status of said one or more cells, tissues and/or organs to thereby elicit an immune response that is beneficial to the mammal. The method of immunotherapy avoids or minimizes lasting damage to the treated cells, tissues and/or organs.
Ellex Medical Pty Ltd.


07/16/15
20150196666 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196665 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196664 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196662 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196661 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196654 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196653 

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity


The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


07/16/15
20150196626 

Modulation of yeast-based immunotherapy products and responses


Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions..
The Regents Of The University Of Colorado, A Body Corporate


07/09/15
20150191525 

Ox40l fusion protein for the immunotherapy of tumors of veterinary animals


Provided is an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine ox40l extracellular domain polypeptide fragment or a biological equivalent thereof and compositions comprising: an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine ox40l extracellular domain polypeptide fragment; and a pharmaceutically acceptable carrier. Also provided are methods for treating or ameliorating the symptoms of cancer in a canine comprising administering an effective amount of the isolated recombinant polypeptide of the disclosure and/or a composition of the disclosure to a canine in need thereof..

07/09/15
20150191516 

Ly6k epitope peptides for th1 cells and vaccines containing the same


Isolated ly6k-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


07/09/15
20150190490 

Cdca1 epitope peptides for th1 cells and vaccines containing the same


Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


07/09/15
20150190489 

Kif20a epitope peptides for th1 cells and vaccines containing the same


Isolated kif20a-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science. Inc.


07/09/15
20150190386 

Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl) piperidine-2,6-dione in combination with second active agents


Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation


07/09/15
20150190380 

Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders


Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of sns-595.
Sunesis Pharmaceuticals, Inc.




Immunotherapy topics: Immunotherapy, Therapeutics, Antibodies, Immune Response, Monoclonal, Monoclonal Antibody, Stimulator, Immunostimulator, Compatibility, Histocompatibility, Specificity, Major Histocompatibility Complex, Radiation Therapy, Treatments, Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.2578

5175

0 - 1 - 104